.jpg "uniQure NV (NASDAQ: QURE)")
In a report released yesterday, Ritu Baral from Cowen & Co. maintained a Buy rating on uniQure NV (NASDAQ: QURE). The company’s shares opened today at $35.47, close to its 52-week high of $40.99.
According to TipRanks.com, Baral is a top 100 analyst with an average return of 33.5% and a 56.3% success rate. Baral covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals Inc, Allena Pharmaceuticals Inc, and Ionis Pharmaceuticals Inc.
uniQure NV has an analyst consensus of Strong Buy, with a price target consensus of $49.17, which is a 38.6% upside from current levels. In a report issued on August 8, Janney Montgomery also maintained a Buy rating on the stock.
.
See today’s analyst top recommended stocks >>
The company has a one-year high of $40.99 and a one-year low of $7.52. Currently, uniQure NV has an average volume of 337.6K.
Based on the recent corporate insider activity of 32 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
uniQure NV engages in the research, development, and commercialization of gene therapies. Its discoveries intend to treat hemophilia, Huntington’s disease, glybera, and cardiovascular problems. The company was founded on January 9, 2012 and is headquartered in Amsterdam, the Netherlands.
